Objective-Inactivating peroxisome proliferator-activated receptor-γ (PPARγ) mutations lead to a syndrome of familial partial lipodystrophy (FPLD3) associated with early-onset severe hypertension. PPARγ can repress the vascular reninangiotensin system (RAS) and angiotensin II receptor 1 expression. We evaluated the relationships between PPARγ inactivation and cellular RAS using FPLD3 patients' cells and human vascular smooth muscle cells expressing mutant or wild-type PPARγ. Approach and Results-We identified 2 novel PPARG mutations, R165T and L339X, located in the DNA and ligand-binding domains of PPARγ, respectively in 4 patients from 2 FPLD3 families. In cultured skin fibroblasts and peripheral blood mononuclear cells from the 4 patients and healthy controls, we compared markers of RAS activation, oxidative stress, and inflammation, and tested the effect of modulators of PPARγ and angiotensin II receptor 1. We studied the impact of the 2 mutations on the transcriptional activity of PPARγ and on the vascular RAS in transfected human vascular smooth muscle cells. Systemic RAS was not altered in patients. However, RAS markers were overexpressed in patients' fibroblasts and peripheral blood mononuclear cells, as in vascular cells expressing mutant PPARγ. Angiotensin II-mediated mitogenactivated protein kinase activity increased in patients' fibroblasts, consistent with RAS constitutive activation. Patients' cells also displayed oxidative stress and inflammation. PPARγ activation and angiotensin II receptor 1 mRNA silencing reversed RAS overactivation, oxidative stress, and inflammation, arguing for a role of angiotensin II receptor 1 in these processes. Conclusions-Two novel FPLD3-linked PPARG mutations are associated with a defective transrepression of cellular RAS leading to cellular dysfunction, which might contribute to the specific FPLD3-linked severe hypertension. (Arterioscler Thromb Vasc Biol. 2013;33:829-838.)
P eroxisome proliferator-activated receptor-γ (PPARγ) is a ligand-activated transcription factor of the nuclear hormone receptor superfamily expressed in a variety of cell types that plays a prominent role in adipogenesis and insulin sensitivity. 1, 2 PPARγ is also involved in the regulation of vascular tone and blood pressure 3 and is expressed in many components of the vascular system (endothelial and smooth muscle cells, monocytes/macrophages), 4, 5 where it exerts antiinflammatory and antioxidant effects 6, 7 through gene transrepression. 8 Thus, signaling pathways activated by PPARγ in the vasculature contribute to prevent endothelial dysfunction and atherosclerosis. 9, 10 
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Humans with germline-inactivating mutations in PPARG develop a syndrome of familial partial lipodystrophy of the Dunnigan type 3 (FPLD3) characterized by limb and gluteal lipoatrophy, severe hypertension together with diabetes mellitus, insulin resistance, dyslipidemia, and liver steatosis, leading to an increased cardiovascular risk. 2, [11] [12] [13] [14] These clinical manifestations result from loss-of-function and dominantnegative effects of the mutated PPARγ proteins, modified in their DNA (DBD) or ligand (LBD)-binding domains. 15 Compared with patients with other forms of lipodystrophies, patients with FPLD3 have an earlier and more severe hypertension. 16 Hypertension is also associated with PPARγ dysfunction in lipodystrophic human immunodeficiency virus-infected patients under antiretroviral treatment 17 and is observed in animal models of PPARγ dysfunction, such as the knock-in PPARG P465L mice, and to a lower extent, the L466A female mice, 18, 19 with vascular remodeling in the P465L model. 20, 21 Lowering PPARγ expression moderately increased blood pressure in mice 22 and induced vascular dysfunction and phenotypic modulation of vascular smooth muscle cells (VSMCs) during hypertension in rats, 23 which were attenuated by PPARγ ligands.
The mechanism whereby PPARγ modulates blood pressure is poorly understood. In rat VSMCs, PPARγ modulates the renin-angiotensin system (RAS), a major regulator of systemic blood pressure and interstitial fluid volume, by transcriptional repression of angiotensin II receptor 1 (AT1R) expression. 24, 25 Overexpression of AT1R in adipose tissue was proposed to contribute to hypertension observed in obese subjects or in lipoatrophic mice. [26] [27] [28] Otherwise, we previously reported PPARγ dysfunction and AT1R overexpression in adipose cells treated with some human immunodeficiency virus antiretrovirals. [29] [30] [31] The RAS is a dual system involving circulating and local intracellular components that both regulate arterial blood pressure. 32 A local RAS has been identified in several tissues, including the vascular system. 33 It may contribute to control the vascular tone and arterial structure and may amplify vascular effects of the circulating RAS, particularly in pathological conditions, such as hypertension, atherosclerosis, and diabetes mellitus. In some cases, the tissular RAS was proposed to have a more important role in tissue damage than the circulating RAS. 32, 34 To our knowledge, the cellular RAS has never been investigated in human cells bearing naturally occurring PPARG mutations.
In the present study, we identified and characterized still unreported PPARG mutations, R165T in the DBD and L339X in the LBD, in 4 patients from 2 families presenting with lipodystrophy and severe hypertension, without systemic RAS alterations. We evaluated the impact of these PPARγ-inactivating mutations on cellular RAS, oxidative stress, and inflammation in patients' cultured skin fibroblasts and circulating blood cells. We also tested the impact of the mutations in human VSMCs transfected with wild-type (WT) or mutant PPARγ.
Patients and Methods
Patients and Methods are available in the online-only Supplement.
Results

Identification of 2 Novel PPARγ Mutations
We identified 2 previously unreported heterozygous PPARG substitutions, R165T (44-year-old mother and 22-year-old daughter) and L339X (70-year-old father and 40-year-old son), in 4 patients from 2 families with FPLD3. Clinical presentation was typical of FPLD3 in all patients, with peripheral lipoatrophy, muscular hypertrophy, insulin resistance (with diabetes mellitus in 3 patients), hypertriglyceridemia, liver steatosis, and severe hypertension (Table) . The 2 patients with the L339X mutation also presented with extensive psoriasis lesions. Treatment with thiazolidinediones strikingly improved hyperglycemia in the 3 diabetic patients. In the 2 patients previously treated with insulin, thiazolidinediones allowed to markedly reduce or even stop high-dose insulin therapy (2 U/kg per d at the time of diagnosis). Regarding systemic renin-angiotensin regulation, none of the patients had low-potassium levels. However, because of the severe hypertension, which requires the use of several medications, measurements of circulating renin and angiotensin were difficult and were reliably investigated in 2 patients only. The 22-year-old woman with the PPARG R165T mutation and the 40-year-old man harboring the L339X mutation had normal values of plasma renin and aldosterone, both in supine and upright position, as well as normal levels of urine aldosterone. The addition of AT1R blockers to their antihypertensive regimen significantly improved hypertension in all patients. Clinical and biological data are detailed in the Table. Arginine 165 (according to the PPARγ2 nomenclature) is a residue preserved among PPAR species and nuclear receptors ( Figure 1A ). In this highly conserved region of the DBD (residues 139-192), 5 missense mutations (C142R, Y151C, C159Y, C190S, and C190W) have been associated with FPLD3 with severe hypertension. [35] [36] [37] Leucine 339 is conserved among PPARγ species and in PPARα and δ ( Figure 1A ). The nonsense L339X mutation predicted a protein truncation within the central part of the LBD, as described in other natural FPLD3-linked PPARG mutations, that is, the dominant-negative Fs343X and R385X mutations that alter PPAR/RXR dimerization 35 and the Y355X alteration, which acts via a haploinsufficiency mechanism. 38 Several somatic PPARγ amino acid substitutions close to residue 339 have been found in sporadic colorectal cancers, and the germline dominant-negative PPARG S317C substitution was associated with colorectal cancer and dyslipidemia in a family. 39 Interestingly, a screening colonoscopy revealed several polyps, without dysplasia, in the 40-year-old patient with the L339X mutation.
PPARγ was similarly expressed in control and patients' fibroblasts at both the protein ( Figure 1B ) and mRNA levels (data not shown). As shown by cDNA sequencing, both the normal and R165T-mutated alleles were expressed in patients' peripheral blood mononuclear cells (PBMCs; data not shown). In cell lysates from L339X-mutated fibroblasts and PBMCs, 2 bands of 55 and 40 kDa were revealed by N-terminal PPARγ antibodies, corresponding to the WT and truncated forms of the protein, respectively. The latter form was not detected with C-terminal PPARγ antibodies ( Figure 1B ). Similar patterns of PPARγ protein expression were observed in human VSMCs ( Figure 1B ) or human embryonic kidney (HEK)-293 cells (not shown) transfected with WT, R165T-, or L339X-mutant PPARγ.
In HEK-293 cells transfected with R165T-or L339Xmutant PPARγ, the basal PPARγ transcriptional activity was markedly decreased (by 70%-80%) as compared with that measured in cells transfected with WT PPARγ ( Figure 1C ). As expected, rosiglitazone increased PPARγ basal transcriptional activity of cells transfected with WT PPARγ (by 2-fold), whereas in mutant cells the effect of rosiglitazone only reached 30% to 40% of that observed in cells transfected with WT PPARγ. However, R165T-or L339X-mutant PPARγ failed to significantly suppress WT-driven transcription indicating that the 2 mutations lacked dominant-negative activity and probably acted through a haploinsufficiency mechanism ( Figure 1C ).
PPARγ Mutations Modulate the Cellular RAS
The basal protein expression of AT1R, renin, and angiotensinogen (AGT) was barely detectable in control cells but was markedly increased in R165T-and L339X-mutated fibroblasts (Figure 2A ; 5-to 7-fold, 9-to 10-fold, and 13-to 16-fold increase, respectively). AT1R, renin, and AGT overexpression was also observed in PBMCs from the patients bearing the PPARG mutations (5-to 7-fold increase) and in human VSMCs transfected with R165T-or L339X-mutant PPARγ (Figure 2A ; 9-, 4.5-, and 4.1-fold increase versus WT PPARγ, respectively), but not in human VSMCs transfected with WT-PPARγ. A short-term treatment with angiotensin II (100 nmol/L, 10 minutes) activated extracellular-signal-regulated kinase1/2 in patients' fibroblasts to a higher level than in control fibroblasts ( Figure 2B ; 4.4-to 6.2-fold increase). A similar alteration of the RAS markers was observed in HEK-293 cells transfected with mutant PPARγ (data not shown). These studies indicated that the 2 PPARγ mutations deregulate the cellular RAS in all cell types studied, including vascular cells. 
Table. Main Clinical and Biological Features of Patients
PPARγ Mutations Induce Oxidative Stress and Inflammation
The 2 PPARG mutations increased reactive oxygen species production in patients' fibroblasts, as demonstrated by the 5to 6-fold and the 2.5-to 3-fold increase of CM-H 2 DCFDA oxidation and nitro blue tetrazolium reduction, respectively ( Figure 3A) . The secretion of the inflammation markers interleukin-6 and MCP-1 also increased by 3-to 3.7-fold and 2.2to 2.8-fold, in PPARG-mutated versus control fibroblasts, respectively ( Figure 3B ), in the same range whatever the mutation and the patient (not shown). Activation of the inflammation signaling was further demonstrated by the increased expression of the phosphorylated form (serine 536) of the p65/RelA subunit of nuclear factor κ-B in patients' fibroblasts (15-fold increase) and PBMCs (3-to 4-fold increase), as compared with control cells ( Figure 3C ).
Effects of the Modulators of PPARγ, Rosiglitazone, and GW9662
The strong pharmacological activator of PPARγ, rosiglitazone, markedly improved cell dysfunctions induced by heterozygous PPARG mutations. Incubation of cells with rosiglitazone decreased AT1R, renin, and AGT overexpression observed in patients' fibroblasts by 2-to 4-fold ( Figure 4A ). Rosiglitazone treatment also decreased oxidative stress, evaluated by nitro blue tetrazolium reduction (by 2.4-to 3.3-fold), and inflammation, assessed by interleukin-6 secretion (by 3.1-to 3.8-fold; Figure 4B ), and p65 nuclear factor κ-B phosphorylation (by 4.2-to 6.8-fold; Figure 4A ) in R165T-and L339X-mutated fibroblasts without modifying the basal level in control cells. Thus, forced activation of PPARγ by rosiglitazone in cells bearing heterozygous mutations in the PPARG gene could partly reverse RAS overactivation and subsequent oxidative stress and inflammation, consistent with the results of the transactivation studies.
Conversely, the irreversible inhibition of WT PPARγ by GW9662 in control fibroblasts ( Figure 4C ) markedly enhanced AT1R, renin, and AGT expression, and triggered oxidative stress, evaluated by nitro blue tetrazolium reduction (3.5-fold increase), and inflammation, assessed by nuclear factor -κB activation (3.2-fold increase). These data further argue for the ability of PPARγ to repress RAS activation and indicate that RAS overactivation is associated with oxidative stress and inflammation.
AT1R mRNA Silencing Decreases Oxidative Stress and Inflammation Resulting From PPARγ Mutations
To directly evaluate the consequences of RAS inhibition, we silenced AT1R mRNA by using siRNA. As expected, AT1R siRNAs blocked AT1R overexpression in R165T-and L339Xmutated fibroblasts (5.9-to 7.4-fold decrease, Figure 5A ) without affecting control cells (data not shown), in which AT1R expression was minimal (Figures 2A and 4A ). Renin and AGT overexpression was also partly decreased by AT1R mRNA silencing (by 2.3-to 4.6-fold; Figure 5A ). Scrambled siRNAs, used as controls, had no effect on AT1R, renin, and AGT overexpression (data not shown). Interestingly, AT1R mRNA silencing reduced oxidative stress (evaluated by nitro blue tetrazolium reduction, by 2.5-fold) and inflammation (measured by interleukin-6 secretion, by 5-fold) resulting from PPARG mutations ( Figure 5B) , arguing for the role of AT1R in these cell dysfunctions. Scrambled siRNA had no effect.
As well, the constitutive activation of nuclear factor-κB observed in R165T-and L339X-mutated fibroblasts was completely reversed by AT1R mRNA silencing ( Figure 5C ), further stressing the importance of AT1R overactivation in cellular inflammation resulting from PPARG mutations.
Discussion
We report here that components of the cellular RAS were markedly overexpressed and activated in fibroblasts and PBMCs issued from 4 patients with FPLD3 attributable to novel PPARγ mutations. PPARG mutations also induced oxidative stress and inflammation in patients' fibroblasts. The adverse effects of the PPARγ mutations were reproduced in VSMCs overexpressing the R165T-or L339X-mutant PPARγ. The ability of a pharmacological agonist of PPARγ (rosiglitazone) and of AT1R silencing (AT1R siRNA) to reverse these dysfunctions led us to suggest that AT1R activation resulting from PPARG mutations might contribute, through vascular RAS overactivation, to the severe hypertension associated with FPLD3.
We identified 2 novel heterozygous germline PPARG mutations, R165T and L339X. Affected individuals exhibited a typical FPLD3 phenotype with early onset severe hypertension, transmitted as an autosomal dominant trait. The 2 mutations involved highly conserved residues in the PPARγ sequence, either an arginine (R165) within the DBD, or a leucine (L339) within the LBD, which induced PPARγ truncation, as confirmed by the protein expression analysis. The pathogenicity of the R165T variant could result from the loss of hydrogen bond formation by the positively charged arginine. The substituted threonine is, however, not predicted to turn out to be a new site of phosphorylation (http://www.cbs.dtu.dk/ services/NetPhos). In the same region of the DBD, several other human natural PPARγ amino acid substitutions, leading to loss-of-function or dominant-negative effects, have been reported resulting in FPLD3 with severe hypertension. [35] [36] [37] Leucine 339 is located in helix 3 close to other residues (S317, V318, K329, K347) interacting with helix 12 and involved in the stabilization of corepressor complexes. 40 Other naturally occurring PPARG mutations leading to LBD truncation, either acting via a dominant-negative or a haploinsufficiency mechanism, were responsible for typical FPLD3. 35, 38 We demonstrated using a reporter gene assay in HEK-293 cells that these 2 new mutations, R165T and L339X, repressed basal and ligand-induced PPARγ transcriptional activity and acted via a loss-of-function mechanism.
We studied the fibroblasts and PBMCs from these 4 severely hypertensive patients. Whatever the mutation, R165T or L339X, patients' cells exhibited increased levels of tissular RAS components, including AT1R, renin, and AGT, with overactivation of angiotensin II signaling together with oxidative stress and inflammation. Several arguments indicate that RAS overactivation might play a role in the cellular consequences of PPARγ inactivation as follows: (1) RAS overactivation and cellular dysfunctions observed in PPARGmutated fibroblasts were reversed, at least partially, by the PPARγ agonist rosiglitazone, and, conversely, were induced in control cells by the strong PPARγ antagonist GW9662 and (2) AT1R mRNA silencing, which decreased RAS markers as expected, reversed oxidative stress and inflammation in PPARG-mutated fibroblasts. These data indicated that the patients' cell dysfunctions may result from AT1R overactivation induced by PPARG mutations. AT1R overactivation has been reported to have damaging consequences not only on cell cultures but also in animal studies and clinical intervention trials. 41 In patients with essential hypertension, blockade of AT1R reduced the expression of markers of oxidative stress and inflammation and improved endothelial function and arterial stiffness. 42 Otherwise, several studies have reported that PPARγ can directly repress AT1R by acting at the Sp1 site level. 24, 25, 43, 44 The mechanism whereby these new PPARγ mutations prevented PPARγ-induced repression of AT1R expression and activity deserves further studies.
Whether AT1R overactivation measured on patients' fibroblasts or PBMCs had an influence on the patients' vascular system is not obvious, and we did not bring evidence of systemic RAS overactivation in these patients. However, PPARγ is expressed in the vascular system where it locally exerts a protective role 10, 16 by the control of endothelial cell function, smooth muscle cell proliferation, and migration, 9, 45 and of the phenotype of arterial wall macrophage foam cells. 5, 46 In VSMCs, PPARγ constitutively represses several genes involved in atherogenesis and angiogenesis, 23, 47, 48 including components of the tissular RAS, stressing the importance of this system in the pathophysiology of hypertension.
When we tested the effect of these 2 PPARγ mutations on human VSMCs, we demonstrated that RAS components were overexpressed in human VSMCs transfected with mutant, but not WT PPARγ. These data reinforce the hypothesis that these PPARγ mutations may deregulate the patients' vascular RAS, thus playing a role in their hypertension. The relative importance of the vascular versus the systemic RAS has recently emerged. In certain pathological conditions and cell types, particularly hypertension, atherosclerosis, and diabetes mellitus, the intracrine pathways may be the dominant mechanism of angiotensin II effect, 32 which may function independently of the circulating RAS. 49 Thus, our results strongly suggest that AT1R activation resulting from PPARG mutations might contribute to severe hypertension associated with FPLD3.
Our results also indicate that PPARγ agonists, but also AT1R blockers, might be beneficial on the long term for the treatment of patients with FPLD3. Because the use of thiazolidinediones is at present restricted or even forbidden in some countries, it might be relevant for the patients to use therapeutic molecules that both inhibit the RAS and have a PPARγ agonist activity, 43, 50 as AT1R blockers, which were efficient to control blood pressure in these patients. Other PPARγ modulators targeted against the complex post-transcriptional modifications of PPARγ have become a topic of therapeutic interest. Their capacity to restore a normal PPARγ transrepression mechanism of the RAS together with improved insulin signaling in the patients' cells should be evaluated. 8, 51 In conclusion, our data suggest that severe hypertension, which is a peculiar feature of patients with FPLD3 versus other lipodystrophic syndromes, might be linked to tissular RAS overactivation resulting from PPARγ dysfunction. In addition, overactivation of AT1R signaling could participate in cellular oxidative stress and inflammation observed in PPARG-mutated cells, stressing the important role of the tissular RAS in these cell functions. 
